LPCN – lipocine inc. (US:NASDAQ)
Stock Stats
News
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)
Lipocine (NASDAQ:LPCN) was upgraded by analysts at Wall Street Zen f
Buy Rating Maintained on Lipocine Inc. (LPCN) as Target Climbs to $15 [Yahoo! Finance]
Lipocine (NASDAQ:LPCN) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Form 8-K Lipocine Inc. For: Feb 18
Form 8-K Lipocine Inc. For: Feb 18
Form SCHEDULE 13G/A Lipocine Inc. Filed by: Squadron Capital Management LLC
Form 8-K Lipocine Inc. For: Jan 20
Form 8-K Lipocine Inc. For: Jan 12
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.